What Happened?
Shares of clinical research company IQVIA (NYSE: IQV) jumped 12.9% in the morning session after the company reported second-quarter results that surpassed Wall Street's expectations and raised its full-year guidance. The company posted revenue of $4.37 billion, an 8.7% increase year-over-year, which beat estimates of $4.30 billion. Its adjusted earnings per share came in at $3.15, up 12.1% from the previous year and topping the consensus estimate of $3.03.
Following the strong performance, IQVIA lifted its full-year 2026 forecast, now projecting revenue between $17.28 billion and $17.48 billion and adjusted earnings per share in the range of $12.80 to $13.00.
Is now the time to buy IQVIA? Access our full analysis report here, it’s free.
What Is The Market Telling Us
IQVIA’s shares are somewhat volatile and have had 12 moves greater than 5% over the last year. But moves this big are rare even for IQVIA and indicate this news significantly impacted the market’s perception of the business.
The previous big move we wrote about was 27 days ago when the stock gained 5.8% on the news that Baird raised its price target on the stock to $249 from $230 and designated it a 'bullish Fresh Pick'. The firm maintained its 'Outperform' rating on the shares. The clinical trials market is undergoing a significant transformation driven by artificial intelligence. IQVIA is considered a key player in this evolving landscape, which is seeing substantial investment activity, positioning the company to benefit from the industry's shift toward AI-integrated solutions.
IQVIA is up 6.5% since the beginning of the year, and at $240.04 per share, it is trading close to its 52-week high of $244.29 from January 2026. Despite the year-to-date gain, investors who bought $1,000 worth of IQVIA’s shares 5 years ago would now be looking at only $978.27.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
